Mosaic Family Wealth Partners LLC Acquires 6,774 Shares of AbbVie Inc. $ABBV

Mosaic Family Wealth Partners LLC boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 108.2% during the second quarter, Holdings Channel.com reports. The firm owned 13,033 shares of the company’s stock after acquiring an additional 6,774 shares during the period. Mosaic Family Wealth Partners LLC’s holdings in AbbVie were worth $3,280,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Capital Analysts LLC grew its stake in shares of AbbVie by 2.8% in the 2nd quarter. Capital Analysts LLC now owns 7,055 shares of the company’s stock worth $1,776,000 after buying an additional 194 shares in the last quarter. Donaldson Capital Management LLC increased its holdings in shares of AbbVie by 0.7% in the 2nd quarter. Donaldson Capital Management LLC now owns 485,608 shares of the company’s stock worth $122,198,000 after buying an additional 3,553 shares during the last quarter. Colrain Capital LLC raised its position in shares of AbbVie by 0.4% during the 2nd quarter. Colrain Capital LLC now owns 25,047 shares of the company’s stock valued at $6,303,000 after buying an additional 92 shares in the last quarter. Aspire Capital Advisors LLC raised its position in shares of AbbVie by 22.2% during the 2nd quarter. Aspire Capital Advisors LLC now owns 1,227 shares of the company’s stock valued at $309,000 after buying an additional 223 shares in the last quarter. Finally, Innovative Asset Advisors Group LLC lifted its holdings in shares of AbbVie by 5.5% in the 2nd quarter. Innovative Asset Advisors Group LLC now owns 4,797 shares of the company’s stock valued at $1,207,000 after acquiring an additional 248 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ABBV shares. Weiss Ratings raised AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. HSBC reaffirmed a “buy” rating and issued a $300.00 price objective on shares of AbbVie in a research note on Monday, July 6th. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Wells Fargo & Company boosted their target price on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. Finally, Canaccord Genuity Group increased their price target on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $275.95.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $264.61 on Tuesday. The firm has a market capitalization of $467.52 billion, a PE ratio of 74.75, a price-to-earnings-growth ratio of 0.88 and a beta of 0.30. The business has a 50 day simple moving average of $249.34 and a two-hundred day simple moving average of $227.78. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the business posted $2.97 earnings per share. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts expect that AbbVie Inc. will post 14.06 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a $1.73 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.